The 6 most interesting parts of Trump’s mostly disappointing drug price plan image

Vox, May 11, 2018
Dylan Scott, quoting Rachel Sachs (Academic Fellow Alumna)


Read the Full Article

From the article: 

“We’re gonna see those prices go down. It’ll be a beautiful thing to watch,” President Donald Trump said in the Rose Garden on Friday. It’s a big promise. But the actual plan his administration put out doesn’t back it up. In fact, stocks for pharmaceutical companies soared after Trump’s remarks.

”Let me put it this way: what’s the reason to think it would have a significant impact on pricing and spending? Shame? We’ve seen that it doesn’t work,” Rachel Sachs at Washington University in St. Louis told me.

These are all of a kind: making incremental changes to Medicare Part D, the outpatient prescription-drug benefit, so that the health insurers that provide the benefit can negotiate bigger discounts and to make sure that patients themselves aren’t being forced to pay more than necessary.

Those are worthwhile causes. But as Sachs noted on Twitter, “saving money at the pharmacy” is not quite the same as “lower drug prices.”

Read the full article here!

pharmaceuticals rachel sachs